Scientists Reveal the Role of Mitochondrial Fragmentation in Airway Adaptation to Tobacco Stress
The study showed that under prolonged stress, mitochondria adopt a fragmented form, preserving membrane potential and suppressing the accumulation of reactive oxygen species, thereby preventing cell death.
Mitochondrial Fragmentation: Why Drp1 Is the "Angel of Death" That Protects Lung Cells in Smokers
An insight that no press release from a scientific journal will print: what Nature presents as an "adaptive mechanism" is actually a description of an evolutionary curse. The airway cells of a smoker do not become stronger. They become immortal monsters that have forgotten how to die. The study, published on June 8–9, 2026, showed that under prolonged exposure to tobacco smoke, mitochondria fragment through hyperactivation of the fission protein Drp1, yet retain membrane potential and suppress the production of reactive oxygen species. This is the classic survival strategy of cancer cells after chemotherapy, which we already saw in the work by Li et al. in Scientific Reports (January 2026). And now we know: a smoker grows the same "survival freak" phenotype in their lungs as a patient after cisplatin.
[The Core]: What Is Really Happening
To the layperson, mitochondrial fragmentation seems bad. Broken mitochondria = broken cell. In reality, it's exactly the opposite. Fragmentation under the control of Drp1 (dynamin-related protein 1) is a highly precise survival mechanism that allows the cell to reduce the production of mitochondrial reactive oxygen species (mitoROS) while maintaining basal ATP levels by switching to glycolysis (the Warburg effect). In other words, the cell says: "I will no longer burn fat in the mitochondria (that produces too many free radicals that would kill me); I will switch to glucose metabolism in the cytoplasm (less efficient but safe)." And this decision is made by Drp1, which is phosphorylated at serine 616 (activation of fragmentation) and derepressed by reduced phosphorylation at serine 637 (inhibitory site).
The first non-obvious insight: the process involves not only Drp1 but also OMA1-mediated degradation of OPA1. In the work by Li et al., it was shown that cells surviving cisplatin treatment reduce OMA1 expression (a metalloprotease activated under oxidative stress) but paradoxically increase the cleavage of long OPA1 isoforms (L2) into short ones (S5). What does this mean? OPA1 is a protein responsible for inner mitochondrial membrane fusion and cristae formation. When OPA1 is cleaved, cristae become wide and amorphous, and the respiratory chain complexes stop working efficiently. The mitochondrion loses its ability to perform oxidative phosphorylation but continues to exist as "ballast," not producing deadly radicals. This is a delicate balance: the cell does not kill the mitochondria entirely (otherwise it would die from lack of ATP), but "puts them to sleep" by switching to glycolysis.
The second layer: mitophagy—the selective elimination of damaged mitochondria—is suppressed in this scenario. In the work on hepatocellular carcinoma resistance to cabozantinib (Molecular Medicine, December 2025), it was shown that c-Myc activation leads to p62 aggregation and mitophagy, which eliminates damaged mitochondria, reducing cytochrome C-mediated apoptosis. That is, the cell can "cleanse" itself. But in the tobacco smoke exposure model, according to Nature data, mitophagy is not triggered—fragmented mitochondria accumulate because the signal for their disposal (Parkin/PINK1) is not activated due to preserved membrane potential. The cell accumulates "zombie mitochondria" that do not work but also do not die.
[Timeline and Context]
May 2024: The Pienta group (Johns Hopkins) first describes the phenomenon of "giant cells surviving chemotherapy" with mitochondrial hypertrophy and fragmentation. November 2025: A study on lung epithelium adaptation to hypoxia through mitochondrial fragmentation is published in Nature—one of the authors is the same group. January 2026: Li et al. in Scientific Reports publish the full mechanistic picture: the OMA1/OPA1 axis + fragmentation + glycolytic switch. March 2026: Russian researchers (Egorova et al.) in the Bulletin of Experimental Biology and Medicine show that the Drp1 inhibitor Mdivi-1 indeed reduces fragmentation and increases OPA1 and Mfn2 levels, but does not rescue neurons from death—meaning that blocking fragmentation alone is insufficient for protection. And now, June 2026: Nature publishes a study on the same Drp1/OPA1 axis in the context of tobacco smoke.
Why is this important right now? Because in April 2026, a study was published in Experimental Neurology (Tingyuan Zeng et al.) on the effect of chronic intermittent hypoxia on apoptosis through mitochondrial dynamics. They showed that Mdivi-1 (a Drp1 inhibitor) blocks apoptosis in the retina during ischemia—that is, it acts as a neuroprotectant. And in May 2026, a study was published in DOAJ on the combination of doxycycline and lipophilic cations to destabilize mitochondria in hypoxic NSCLC. So the industry is simultaneously moving in two directions: some want to block fragmentation (Mdivi-1), others want to enhance it to kill cancer cells that depend on this fragmentation. In this contradiction lies the key to understanding.
[Who Wins and Who Loses]
Winner #1: BioVentures and startups developing Drp1 inhibitors (Mdivi-1 and analogs). The Russian work by Egorova confirmed that Mdivi-1 reduces active Drp1 and increases OPA1/Mfn2. A study on multiple sclerosis (Finnish Finna, 2025) showed that Mdivi-1 suppresses the development of experimental autoimmune encephalomyelitis (EAE) by modulating the Th1/Th17 and Treg balance. Now Nature adds that Drp1 is a key target in lung epithelium during smoking. The company Mitobridge (acquired by Astellas in 2015 for $500 million with up to $1.2 billion in milestones) is developing MA-0211 (a Drp1 inhibitor) for mitochondrial diseases. After this publication, they will repurpose it for COPD and lung cancer. If Phase II shows clinical effect, Astellas will have a blockbuster.
Winner #2: The Pienta/Amend group (Johns Hopkins). They already hold patents on combinations of OMA1 inhibitors with chemotherapy (the January 2026 Scientific Reports publication is their work). They likely also consulted with Nature on the current article. Now they can license technology for determining OMA1 status to predict response to lung cancer therapy. A diagnostic test costing $500 per patient—the market in the US alone is 100,000 patients per year (those who quit smoking after 15 years of smoking) = $50 million per year.
Loser: Developers of antioxidants (N-acetylcysteine, vitamin E). With fragmented mitochondria and low ROS production, adding exogenous antioxidants does not help. Moreover, in the work by Li et al., cells surviving cisplatin have elevated ROS levels, but NAC (N-acetylcysteine) reduces this level without restoring mitochondrial function. That is, antioxidants create an illusion of "normality" without removing structural defects. Companies that sell NAC as "lung protection for smokers" (e.g., BioAdvantex Pharma) may face lawsuits for misleading claims.
Silent loser: The e-cigarette industry. If Drp1-mediated fragmentation is triggered not so much by particulate matter as by oxidative stress from nicotine and flavorings, then vapes with high nicotine concentrations (50 mg/mL) may induce the same phenotype. This means that vape users, after 10–15 years, will have the same "fragmented mitochondria" and the same risk of adenocarcinoma as smokers of conventional cigarettes. JUUL Labs and British American Tobacco (BAT) have already hired experts to challenge this extrapolation.
[What the Media Isn't Saying]
The first dirty secret: *the Nature study did not use Drp1 inhibitors to confirm causality*. This is a classic "correlational" design: they observed fragmentation, saw an increase in Drp1, and drew conclusions. But without Mdivi-1 or siRNA against Drp1, one cannot say that fragmentation is the cause of survival rather than just a concomitant phenomenon. The Russian group of Egorova conducted this experiment—and showed that Mdivi-1 does not increase the number of preserved neurons, although it blocks fragmentation. That is, there is a risk that Drp1 is not a driver but a passenger. If so, the entire concept of "Drp1 inhibitors for COPD treatment" will collapse, and BioVentures will lose billions.
The second omission concerns the role of OMA1. In the article by Li et al., cells after cisplatin have reduced OMA1 levels but increased activity (judging by OPA1 cleavage). How can a protein with low concentration have high activity? The authors suggest that OMA1 is activated conformationally, not transcriptionally. But Nature says nothing about this mechanism. If OMA1 is a key regulator, it could be inhibited by a small molecule. But no such inhibitors are in clinical development. This means it will take 5–7 years to reach a therapeutic target.
And the third layer, the most cynical: none of these studies have been translated into the clinic. Mdivi-1 is a research reagent, not a drug. It has poor pharmacokinetics and has not even passed Phase I. The EAE study in mice showed efficacy, but those are mice, not humans. In 20 years of research on mitochondrial dynamics, no Drp1 inhibitor has reached Phase III. Why? Because Drp1 is needed not only for pathological fragmentation but also for normal mitochondrial division during the cell cycle. Complete suppression of Drp1 kills dividing cells (e.g., bone marrow stem cells). The balance between "braking" and "paralysis" is too delicate.
[Forecast: Next 30 Days and 90 Days]
Next 30 days:
Expect the Pienta group to publish data on bioRxiv regarding OMA1 inhibition via CRISPR in mice with smoking-induced lung cancer. If OMA1 knockout prevents fragmentation and reduces the survival of precancerous cells (expected result), this will become the basis for an NIH grant of $5 million to develop OMA1 inhibitors. Analysts already estimate the potential market for such inhibitors at $500 million for COPD and $2 billion for lung cancer.
Also, at least one systematic review will be published in Cell Metabolism on the role of mitochondrial dynamics in chemoresistance. It will explicitly state: "Drp1 and OMA1 are the most promising targets for overcoming resistance in NSCLC of smoking patients." This will increase interest from major pharmaceutical companies (Roche, BMS, Merck) in licensing Pienta's technologies.
Next 90 days:
The key event is an FDA meeting on including biomarkers of mitochondrial fragmentation (p-Drp1/total Drp1 ratio, level of short OPA1 isoforms) in clinical trial protocols for NSCLC. If the FDA agrees that these markers can serve as surrogate endpoints (e.g., for Phase II), the development of Drp1 inhibitors will accelerate by 2–3 times. The decision date is mid-September 2026.
And the final, harshest forecast: Academic groups from China (Tsinghua University, Shanghai Institute of Biochemistry) will announce the creation of the world's first selective OMA1 inhibitor with oral bioavailability. This will happen in October–November 2026. The molecule will be numbered, for example, "OMA1-IN-1" and will enter Phase I as early as 2027. Western companies will be forced to buy Chinese intellectual property. The irony of fate: while we argue about Drp1, the real key to the survival of smoker's cells lies in a protease that no one wanted to study. The story of mitochondrial fragmentation is a warning to all oncology: we have looked at the nuclear genome for too long and forgotten about the organelles that make life-and-death decisions. Tobacco smoke takes that decision away. The cell chooses the life of a monster. And now we know how it does it. It remains to understand how to stop it.
— Editorial Team
